Baird Initiates Coverage On Xenon Pharmaceuticals with Outperform Rating, Announces Price Target of $63
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney has initiated coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with an Outperform rating and set a price target of $63.
December 08, 2023 | 10:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Brian Skorney initiated coverage on Xenon Pharmaceuticals with an Outperform rating and a price target of $63.
The initiation of coverage by Baird with an Outperform rating typically indicates a positive outlook on the stock's future performance. The price target of $63 suggests a significant upside from the current trading price, which may lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100